High expression of CD147 and MMP-9 is correlated with poor prognosis of triple-negative breast cancer (TNBC) patients

Medical Oncology

Volumn 30, Issue 1, 2013, Pages

  Zhao, Shu ^a   Ma, Wenjie ^a   Zhang, Minghui ^a   Tang, Dabei ^a   Shi, Qingtao ^a   Xu, Shanqi ^a   Zhang, Xiaosan ^a   Liu, Yupeng ^a   Song, Ying ^a   Liu, Leyuan ^b   Zhang, Qingyuan ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Cancer prognosis; CD147; MMP 9; Triple negative breast cancer

Indexed keywords

CD147 ANTIGEN; GELATINASE B; BSG PROTEIN, HUMAN; CELL SURFACE RECEPTOR; MMP9 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FIBROMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MAMMARY GLAND; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; TUMOR INVASION; BIOSYNTHESIS; BREAST TUMOR; CANCER GRADING; CANCER STAGING; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; ANTIGENS, CD147; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, CELL SURFACE; TUMOR MARKERS, BIOLOGICAL;

EID: 84880636957     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0335-4     Document Type: Article

References (32)

1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumors. Nature. 2000;406:747-52.
2. Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res. 2007;9:R65.
3. Reis-Filho JS, Tutt AN. Triple negative tumors: a critical review. Histopathology. 2008;52:108-18.
4. Kang SP, Martel M, Harris LN. Triple negative breast cancer: current understanding of biology and treatment options. Curr Opin Obstet Gynecol. 2008;20:40-6.
5. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007;109:1721-8.
6. Tang Yi, Nakada Marian T, Kesavan Prabakaran, et al. Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res. 2005;65:3193-9.
7. Toole BP. Emmprin (CD147), a cell surface regulator of matrix metalloproteinase production and function. Curr Top Dev Biol. 2003;54:371-89.
8. Zheng HC, Takahashi H, Murai Y, et al. Upregulated EMM-PRIN/CD147 might contribute to growth and angiogenesis of gastric carcinoma: a good marker for local invasion and prognosis. Br J Cancer. 2006;95:1371-8.
9. Li Z, Ren Y, Wu QC, et al. Macrophage migration inhibitory factor enhances neoplastic cell invasion by inducing the expression of matrix metalloproteinase 9 and inter-leukin-8 in nasopharyngeal carcinoma cell lines. Chin Med J. 2004;117:107-14.
10. HymowitzM Zucker, Rollo EE, et al. Tumorigenic potential of extracellular matrix metalloproteinase inducer. Am J Pathol. 2001;158:1921-8.
11. Mira E, Lacalle RA, Buesa JM, et al. Secreted MMP9 promotes angiogenesis more efficiently than constitutive active MMP9 bound to the tumor cell surface. J Cell Sci. 2004;117:1847-57.
12. Yu WW, Liu JH, Xiong XL, et al. Expression of MMP-9 and CD147 in invasive squamous cell carcinoma of the uterine cervix and their implication. Pathol Res Pract. 2009;205:709-15.
13. Tang J, Zhou HW, Jiang JL, et al. ßig-h3 is involved in the HAb18G/CD147-mediated metastasis process in human hepatoma cells. Exp Biol Med. 2007;232:344-52.
14. Davidson B, Goldberg I, Berner A, et al. EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. Clin Exp Metastasis. 2003;20:161-9.
15. Ramos-DeSimone N, Hahn-Dantona E, Sipley J, et al. Activation of matrix metalloprotease-9 (MMP-9) via converting plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem. 1999;274:13066-76.
16. Alizadeh AA, Ross DT, Perou CM, Ven de Rijn M. Towards a novel classification of human malignancies based on gene expression patterns. J Pathol. 2010;195:41-52.
17. Kashiwagi S, et al. Significance of E-cadherin expression in triple-negative breast cancer. Br J Cancer. 2010;103:249-55.
18. Liu Z, Li L, Yang ZX, et al. Research article Increased expression of MMP9 is correlated with poor prognosis of nasopharyngeal carcinoma. BMC Cancer. 2010;10:270-5.
19. Wang S, Zhou J, Wang XY, et al. Down-regulated expression of SATB2 is associated with metastasis and poor prognosis in colorectal cancer. J Pathol. 2009;219:114-22.
20. Masunaga R, Kohno H, Dhar DK, et al. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res. 2000;6:4064-8.
21. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
22. Li Y, Shang P, Qian AR, et al. Inhibitory effects of antisense RNA of HAb18G/CD147 on invasion of hepatocellular carcinoma cells in vitro. World J Gastroenterol. 2003;9:2174-7.
23. Reimers N, Za frakas K, Assmann V, et al. Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells. Clin Cancer Res. 2004;10:3422-8.
24. Chakraborti S, Mandal M, Das S, et al. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem. 2003;253:269-85.
25. Opdenakker G, Van den Steen PE, Van Damme J, Gelatinase B. A tuner and amplifier of immune functions. Trends Immunol. 2001;22:571-9.
26. Opdenakker G, Van den Steen PE, Dubois B, et al. Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol. 2001;69:851-9.
27. Matache C, Stefanescu M, Dragomir C, et al. Matrix metalloproteinase-9 and its natural inhibitor TIMP-1 expressed or secreted by peripheral blood mononuclear cells from patients with systemic lupus erythematosus. J Autoimmun. 2003;20:323-31.
28. Li Y, Jing X, Li C, et al. HAb18G (CD147), a cancer-associated biomarker and its role in cancer detection. Histopathology. 2009;54:677-87.
29. Piao S, Zhao S, Guo F, et al. Increased expression of CD147 and MMP-9 is correlated with poor prognosis of salivary duct carcinoma. J Cancer Res Clin Oncol. 2012;138:627-35.
30. Ju XZ, Yang JM, Zhou XY, et al. EMMPRIN expression as a prognostic factor in radiotherapy of cervical cancer. Clin Cancer Res. 2008;14:494-501.
31. Chen X, Lin J, Kanekura T, et al. A small interfering CD147-targeting RNA inhibited the proliferation, invasiveness, and metastatic activity of malignant melanoma. Cancer Res. 2006;66:11323-30.
32. Rao JS, Ra C, Gondi C, et al. Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non-small cell lung cancer cells. Mol Cancer Ther. 2005;4:1399-408.